SEC Filings TLDR

On October 29, 2025, Dorothy D. Hayes, a director of Redwire Corp, acquired 19,109 shares of the company's common stock through restricted stock units. These units are set to vest in full on October 29, 2026, contingent upon her continued service with the company through the vesting date. The transaction was reported i...

On October 29, 2025, James McConville, a director of Redwire Corp, acquired 19,109 shares of the company's common stock through restricted stock units. These units will vest in full on October 29, 2026, contingent upon McConville's continued service with the company. The transaction was reported in a Form 4 filing with...

On October 31, 2025, Brian Keith Larabee, Senior Vice President & General Manager - EMS of Rogers Corp, sold 775 shares of the company's common stock at a price of $85.8658 per share. Following this transaction, Larabee owns 4,462 shares of Rogers Corp. The shares sold were part of the company's Global Stock Ownership ...

Matheus De A G Viera Bulho, Senior Vice President of Software and Control at Rockwell Automation, Inc., engaged in several stock transactions on October 29, 2025. He acquired 822 shares of common stock at $350.76 per share, increasing his direct holdings to 1,805 shares. On the same day, he sold 822 shares at $365 per ...

On October 29, 2025, Prahlad R. Singh, President, Chief Executive Officer, and Director of Revvity, Inc., engaged in stock transactions involving the company's common stock. Singh gifted 9,420 shares to an irrevocable trust for the benefit of his children, reducing his direct ownership to 96,838 shares. Simultaneously,...

On October 29, 2025, Lakhmir S Chawla, a director of Revelation Biosciences, Inc., acquired 15,625 shares of common stock at a price of $1.28 per share. This transaction was part of a restricted stock grant under the 2021 Equity Incentive Plan, which vests 100% on January 28, 2026. Following this transaction, Chawla ow...

On October 29, 2025, James Rolke, the Chief Executive Officer of Revelation Biosciences, Inc., acquired 390,614 shares of common stock at a price of $1.28 per share. This transaction was part of a restricted stock grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the grant date. Follo...

On October 29, 2025, Jennifer Carver, a director of Revelation Biosciences, Inc., was granted 15,625 shares of common stock under the company's 2021 Equity Incentive Plan. The shares were granted at a price of $1.28 per share and are set to vest fully on January 28, 2026. Following this transaction, Carver's total hold...

On October 29, 2025, Chester S Zygmont III, the Chief Financial Officer of Revelation Biosciences, Inc., acquired 390,614 shares of common stock at a price of $1.28 per share. This transaction was part of a restricted stock grant under the 2021 Equity Incentive Plan, which vests quarterly over one year from the date of...

On October 29, 2025, Jess Roper, a director of Revelation Biosciences, Inc., was granted 15,625 shares of common stock under the 2021 Equity Incentive Plan. The shares were granted at a price of $1.28 per share and are set to vest 100% on January 28, 2026. Following this transaction, Roper's total holdings in the compa...

Thomas J. Shaw, President and CEO of Retractable Technologies Inc., acquired 15,000 shares of common stock on October 30, 2025, at a weighted average price of $0.861 per share. Following this transaction, Shaw directly owns 15,817,891 shares. Additionally, Shaw has investment power over 500,000 shares as a trustee for ...

Andrew J Murphy, EVP Research at Regeneron Pharmaceuticals, Inc., reported several transactions involving the company's common stock and stock options. On October 29, 2025, Murphy acquired 35,000 shares of common stock at $555.67 per share and disposed of 32,490 shares at $648.82 per share. Additionally, he exercised 3...

Christine A. Poon, a director of Regeneron Pharmaceuticals, Inc., engaged in multiple transactions involving the company's common stock and non-qualified stock options on October 29 and 30, 2025. On October 29, Poon acquired 6,500 shares of common stock at $520.01 per share and disposed of various amounts of shares at ...

On October 31, 2025, Brad Buss, a director of QuantumScape Corp, engaged in multiple transactions involving the company's Class A Common Stock. Buss acquired 300,000 shares at a weighted average price of $6.2336 per share, increasing his direct holdings to 422,476 shares. He also sold 125,000 shares at a weighted avera...

On October 30, 2025, Michael O. McCarthy III, the Chief Legal Officer of QuantumScape Corp, engaged in several transactions involving the company's Class A Common Stock and stock options. McCarthy acquired 50,000 shares of Class A Common Stock at a price of $2.377 per share and subsequently sold the same number of shar...

On October 30, 2025, Joo Mi Kim, the Chief Financial Officer of QUALYS, INC., acquired 34,212 restricted stock units (RSUs) of the company's common stock. These RSUs represent a form of equity compensation that will vest quarterly in equal installments over four years, starting from November 1, 2025, contingent upon Ki...

On October 30, 2025, Sumedh S. Thakar, the CEO and President of Qualys, Inc., acquired 61,092 shares of the company's common stock. This transaction was reported under Form 4 filed with the SEC. The shares were acquired at a price of $0 per share, indicating they were likely granted as part of a compensation package. F...

Bruce K. Posey, the Chief Legal Officer of Qualys, Inc., acquired 20,357 restricted stock units (RSUs) on October 30, 2025. These RSUs represent shares of Qualys' common stock and will vest quarterly in equal installments over four years starting from November 1, 2025, contingent on Posey's continued service through ea...

Patricia Y. Grech, Senior Vice President & Chief Accounting Officer (SVP & CAO) of Qualcomm Inc., was granted 3,729 Restricted Stock Units (RSUs) on October 29, 2025. Each RSU is the economic equivalent of one share of Qualcomm common stock and converts on a one-for-one basis. The RSUs, along with allocable dividend eq...

Patricia K. Wagner, a director of Primoris Services Corp, engaged in several stock transactions on October 29, 2025. She acquired 302 shares of common stock as part of the non-employee director compensation program, with the shares restricted from sale for twelve months. Additionally, she transferred 615 shares of comm...

On August 4, 2025, Christopher D. Olive, the Chief Legal Officer of Phunware, Inc., disposed of 504 shares of common stock at a price of $2.71 per share. This transaction was related to the withholding of taxes pursuant to the terms of the Issuer's 2018 Equity Incentive Plan. Following this transaction, Olive still own...

Diego Scotti, EVP and GM of the Consumer Group at PayPal Holdings, Inc., sold a total of 3,838 shares of common stock on October 30, 2025. The transactions were executed at weighted average prices ranging from $68.406 to $70.2049 per share. Following these transactions, Scotti's ownership in PayPal decreased to 16,989 ...

On October 30, 2025, Suzan Kereere, President of Global Markets at PayPal Holdings, Inc., sold 5,000 shares of the company's common stock at a weighted average price of $69.5244 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 7, 2025. Following the sale, Kereere retains ownersh...

On October 30, 2025, Chris Natali, the VP and Chief Accounting Officer of PayPal Holdings, Inc., sold 1,374 shares of the company's common stock at a price of $69.1318 per share. This transaction resulted in Natali no longer holding any shares of PayPal Holdings, Inc. The sale was reported in a Form 4 filing with the S...

On October 30, 2025, Reeve Emma, a director of PTC Therapeutics, Inc., engaged in several transactions involving the company's common stock. Emma sold 3,666 shares at $69.50 per share, reducing her holdings to 6,666 shares. She also acquired 12,000 shares at $38.10 per share, increasing her holdings to 18,666 shares. S...